PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-13.40%
Cash & equivalents declining -13.40% while RVPH's grows 95.93%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-13.40%
Below half of RVPH's 95.93%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-12.47%
Below half of RVPH's 72.84%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
8.92%
Higher PP&E (Net) Growth compared to RVPH's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
55.91%
Higher Total Non-Current Assets Growth compared to RVPH's zero value, indicating better performance.
No Data
No Data available this quarter, please select a different quarter.
-12.20%
Below half of RVPH's 64.40%. Michael Burry sees a potential red flag for stagnation or capital shortage.
25.71%
Above 1.5x RVPH's 5.25%. Michael Burry questions if payables are being stretched to avoid short-term borrowing.
-32.96%
50-75% of RVPH's -49.51%. Bruce Berkowitz notes the firm is less reliant on near-term borrowing than competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-56.33%
Less than half of RVPH's 8.21%. David Dodd sees fewer expansions in other current obligations.
-28.78%
Less than half of RVPH's 4.94%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-28.78%
Less than half of RVPH's 4.83%. David Dodd sees far fewer liability expansions relative to competitor.
1.95%
Less than half of RVPH's 45.49%. David Dodd sees fewer share issuances vs. competitor.
-3.92%
1.25-1.5x RVPH's -3.55%. Bruce Berkowitz notes stronger reinvestment strategy.
-19.50%
Higher AOCI Growth compared to RVPH's zero value, indicating worse performance.
No Data
No Data available this quarter, please select a different quarter.
-8.72%
Below half RVPH's 89.71%. Michael Burry sees potential underperformance in building shareholder capital.
-12.20%
Below half RVPH's 64.40%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
-32.96%
50-75% of RVPH's -49.51%. Bruce Berkowitz sees relatively smaller yoy debt additions.
13.20%
Less than half of RVPH's -102.37%. David Dodd sees better deleveraging or stronger cash buildup than competitor.